efineptakin alfa

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
efineptakin alfa

GtoPdb Ligand ID: 11097

Compound class: Peptide

Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].

Immunopharmacology Comments
Efineptakin alfa (Hyleukin-7^TM, research code NT-I7), is engineered to induce a persistent and long-lasting anti-tumour T cell response. It acts at multiple levels of T cell development and enhances T cell production, maturation, expansion, and survival, and also improves T cell homing and tumour infiltration. The Fc portion of the fusion protein extends the protein's half-life, and is IgD and IgG4-based so does not induce ADCC or CDC reactions.

Immunopharmacology Comments

Efineptakin alfa (Hyleukin-7^TM, research code NT-I7), is engineered to induce a persistent and long-lasting anti-tumour T cell response. It acts at multiple levels of T cell development and enhances T cell production, maturation, expansion, and survival, and also improves T cell homing and tumour infiltration. The Fc portion of the fusion protein extends the protein's half-life, and is IgD and IgG4-based so does not induce ADCC or CDC reactions.